Биотехнологии переживают избирательное восстановление: капитал и слияния идут только к компаниям с четкой стратегией

Biopharma's selective recovery: Differentiation and strategic clarity define success Mary Clark, CEO of Optimum Strategic Communications, discusses how capital, partnering and M&A now concentrate around credible execution and strategic relevance. The biopharma sector is experiencing what Clark describes as a "selective recovery" rather than a broad market reopening. As CEO of strategic communications firm Optimum, she has a front-row seat to the conversations shaping the industry. Clark sat down with BioXconomy ahead of BIO-Europe in Cologne, Germany, to discuss her overview of the industry. Her assessment is clear: capital is flowing, deal activity is robust and initial public offering (IPO) windows are opening, but only for companies that can demonstrate clear differentiation, credible execution and a compelling rationale for why they matter now. "I am pretty positive," Clark said when asked to characterize the current market environment in 2026. "The market is definitely more selective and more demanding, but it's rewarding companies that can show clear differentiation, credible execution and a strong rationale for why they matter now." The numbers support her optimism. Year-to-date data for 2026 paints a picture of concentrated activity and purposeful decision-making. In the first half of the year, biopharma venture funding reached approximately $16.3 billion across 235 rounds, while biopharma IPOs raised around $5 billion across 13 offerings, already surpassing the full-year totals seen from 2022 to 2025. Announced research and development licensing value reached roughly $166.7 billion, and biopharma mergers and acquisitions (M&A’s) totalled around $96 billion across 80 deals, including 33 transactions valued at $1 billion or more. "The stats on the number of deals being done, financing, IPOs, are all fantastic and better than the previous years," Clark noted enthusiastically. "M&A is definitely notable in terms of the deals being done and the size of the deals being done, in really specific areas like precision oncology and immunology." Activity has concentrated in oncology, immunology and other strategically important therapeutic areas. This includes high-profile transactions such as GSK's acquisition of Nuvalent in precision oncology, AbbVie's purchase of Apogee in immunology, Gilead's acquisition of Arcellx in cell therapy, and multiple Eli Lilly acquisitions across areas such as Centessa Pharmaceuticals and Kelonia Therapeutics. Clark is particularly excited about Novartis' proposed acquisition of UK-based Myricx Bio, backed by Sofinnova, for up to $1.5 billion to strengthen its antibody drug conjugate (ADC) platform in oncology. "Just brilliant," she said. "It strengthens ADCs and the power of that modality." "Across financing, licensing and M&A, we're seeing larger deals, bigger deals, concerning a smaller number of companies," Clark explained. "We're seeing capital and pharma attention around differentiated, late-stage assets with clear pathways." This selectivity has profound implications for how companies communicate their value proposition. Clark argued that the bar has been raised significantly, and companies can no longer rely solely on strong science to capture attention and capital. "From a communications perspective, that raises the bar," she told us. "Companies need to show not just strong science, but why the opportunity matters now, how it fits investor and pharma opportunities, and how it can create durable value in a more disciplined market." For leadership teams, the fundamental question has evolved. "It's no longer a question of how we progress this program," Clark emphasized. "It's how can we make a compelling case for why this matters, why now, and why we are the right team to deliver it. The stronger stories connect science to unmet needs, strategic relevance, commercial logic and long-term value creation." In what Clark described as a hugely competitive market for deals, for people and for finance, companies have got to make sure their story is being heard at the right time and by the right audiences. Partnering as strategic imperative The role of partnering within the industry has also evolved significantly. Partnering has always been important, Clark acknowledged, but before it was perhaps more about business development momentum, capital flow and deal access. Partnering is now much more closely tied to strategic fit, risk-sharing with partners and long-term portfolio planning. "We have the backdrop of regulatory complexity, patent cliffs, artificial intelligence (AI), manufacturing and cross-border sourcing," she said. "And again, that changes the communications side. Why is it compelling? The strongest partners now show clear alignment in science, the development path, the market opportunity and the needs of potential partners." One notable trend is the continuing flow of China-origin licensing deals into Western pharma, where companies are often buying global or ex-China rights to clinically promising assets while using milestone-heavy structures to manage risk. This shift changes the communications challenge fundamentally. In an increasingly complex environment, leadership teams are making decisions across multiple dimensions simultaneously: scientific validity, financing options, partner appetite, development risk, commercial positioning and stakeholder expectations. Clark argued communications become a key part of the strategic decision-making process. "What is the priority? What is differentiated? What matters most to stakeholders? What evidence do we have to support the story?" Clark asked. "It's not enough to explain the science. Companies also need to explain: Why this indication? Why you as the partner? Why this financing route? Why this timing? What's beneficial now?" Clark discussed how one of the biggest risks is fragmented messaging. This is where scientific teams, commercial teams, business development teams and investor-facing teams all tell slightly different versions of the story. "When we have a complex and fragmented market, it's all about what your interpretation and understanding is. In this market, consistency and coherence is a strategic advantage," she said. The value of industry dialogue In a fragmented market, shared industry conversations play an increasingly important role in shaping sentiment, priorities and ultimately decision-making across the sector. Clark sees significant value in shared interpretation. "Industry dialogue makes companies understand how they are going to be perceived, what's happening in the sector, what the concerns are, what is gaining credibility. It means companies need to engage much more." This means companies need the same strategy across events and outside of the company. With lots happening in the world, Europe offers a trusted place, a setting where global players can meet on equal footing. It's not that we're going to replace other hubs, but we can connect US, European and international perspectives. This is a time where we need to share more openly and discuss more freely in the sector. Europe's convening role Clark described how she believes that Europe has a real opportunity to act as a neutral convening ground for biopharma stakeholders. "With lots happening in the world, Europe offers a trusted place, a setting where global players can meet on equal footing," she explained. "It's not that we're going to replace other hubs, but we can connect US, European and international perspectives. This is a time where we need to share more openly and discuss more freely in the sector." When asked what the industry is looking for today from its major conferences, Clark's answer was straightforward. "Major conferences now need to provide useful insights as much as deal flow," she said. "Leaders want forums to test assumptions, understand where consensus is forming and leave with a clear view of where to focus next." The most useful conversations are often not just the scheduled partnering meetings, but the panels, side meetings and informal discussions that reveal where investor appetite, pharma priorities and policy concerns are starting to align. The strongest platforms are those that bring together the full value chain: biotech, pharma, investors, policymakers, service providers and others who influence how innovation moves forward. “For Optimum, we know capital is there, partnering is active, M&A is clearly happening and moving, but the bar is higher," she concluded. "Companies need credible science, a clear strategic fit and a convincing explanation of why their opportunity matters now. That's why good communications and the right industry forums really matter. They help leaders read the signals, build confidence and focus on the decisions that will create value." BIO-Europe Nov 9, 2026 TO Nov 11, 2026 |Cologne, Germany Over the last 30 years, BIO-Europe has become Europe’s flagship partnering event. Its international reach makes it a one-of-a-kind offering, with attendees from all parts of the biotechnology value chain gathering to efficiently identify, engage and form strategic relationships that drive their businesses successfully forward. Read more about: Europe